期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

转移性肾细胞癌靶向治疗进展

原文传递
导出
摘要 肾细胞癌起病隐匿，约20％～30％的患者在就诊时已发生远处转移，局限性肾癌行根治术后亦有30％～40％会发生转移。对转移性肾癌尚无标准治疗方案。随着肿瘤学研究的不断深入，相继有索拉非尼、舒尼替尼、Bevacizumab和Temsimlimus等分子靶向药物应用临床并取得良好的临床效果。现将其临床试验结果、不良反应以及在非透明细胞癌中的应用等方面最新进展作一综述。
作者 王小林(综述) 马茂(审校)
机构地区 西安交通大学医学院第一附属医院老年外科
出处 《国际泌尿系统杂志》 2009年第1期74-77,共4页 International Journal of Urology and Nephrology
关键词 肾细胞肿瘤 靶向治疗
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Patard JJ, Pouessel D, Bensalah K. Targeted therapy in renal cell carcinoma. World Journal of Urology, 2008,26(2) :135 - 140.
  • 2Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 1999,17 ( 8 ) :2530 - 2540.
  • 3张雨涛,陈铌,曾浩,周桥.肿瘤抑制基因VHL、低氧诱导因子与肾细胞癌[J].中华病理学杂志,2006,35(9):562-564. 被引量：6
  • 4Spronsen DJ, Mulders PF, Mulder PH,et al. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol, 2005,55 (3) : 177 - 191.
  • 5Mendel DB, Laird AD, Xin X, et al. In vivo anti -tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res, 2003, 9:327-337.
  • 6Motzer RJ. Sunitinib versus interferon alfa in metastatic renal - cell carcinoma. New England Journal of Medicine, 2007,356 (2):115 - 124.
  • 7Motzer RJ. Sunitinib versus interferon ( IFN ) - alfa as first - line treatment of metastatic renal cell carcinoma (mRCC) : updated efficacy and safety results and further analysis of prognostic factors. Ejc Supplements,2007,5 (4) : 301 - 310.
  • 8Patard JJ, Rioux - Leclercq N, Fergelot p. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol, 2006, 49:633 -643.
  • 9Bukowski RM, Eisen T, Szczylik C. Final results of the randomized phase Ⅲ trial of sorafenib in advanced renal cell carcinoma, survial and biomarker analysis. J Clin Oncol 2007,25 (Suppl) :240s.
  • 10Szczylik C, demkow T, Staehler M. Radomised phase Ⅱ trial of first - line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol, 2007,25 (Suppl) :241 s.

二级参考文献30

  • 1龚侃,张宁,那熙,吴关,杨新宇,辛殿祺,那彦群.散发性肾透明细胞癌组织中希佩尔林道基因突变与缺氧诱导因子1α、2α的测定[J].中华外科杂志,2005,43(6):390-393. 被引量：3
  • 2Latif F,Tory K,Gnarra J,et al.Identification of the von Hippel-Lindau disease tumor suppressor gene.Science,1993,260:1317-1320.
  • 3Eble JN,Sauter G,Sesterhen IA,et al,eds.World Health Organization classification of tumours.Pathology and genetics of the urinary system and male genital organs.Lyon:IARC Press,2004.15-17.
  • 4Maxwell PH,Weisner MS,Chang GW,et al.The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.Nature,1999,399:271-275.
  • 5Lee JW,Bae SH,Jeong JW,et al.Hypoxia-inducible factor (HIF-1) alpha:its protein stability and biological functions.Exp Mol Med,2004,36:1-12.
  • 6Maynard MA,Ohh M.Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.Am J Nephrol,2004,24:1-13.
  • 7Iliopoulos O,Ohh M,Kaelin WG Jr.pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.Proc Natl Acad Sci U S A,1998,95:11661-11666.
  • 8Min JH,Yang H,Ivan M,et al.Structure of an HIF-1[alpha] -pVHL complex:hydroxyproline recognition in signaling.Science,2002,296:1886-1889.
  • 9Jaakkola P,Mole DR,Tian YM,et al.Targeting of HIF-[alpha] to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.Science,2001,292:468-472.
  • 10Hirsila M,Koivunen P,Gunzler V,et al.Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor.J Biol Chem,2003,278:30772-30780.

共引文献5

国际泌尿系统杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部